Historical Valuation
Sanofi SA (SNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.18 is considered Undervalued compared with the five-year average of 10.14. The fair price of Sanofi SA (SNY) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 48.13 USD , Sanofi SA is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：48.13
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sanofi SA (SNY) has a current Price-to-Book (P/B) ratio of 1.39. Compared to its 3-year average P/B ratio of 1.06 , the current P/B ratio is approximately 31.97% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about 44.38% higher. Sanofi SA (SNY) has a Forward Free Cash Flow (FCF) yield of approximately 9.37%. Compared to its 3-year average FCF yield of 4.19%, the current FCF yield is approximately 123.62% lower. Relative to its 5-year average FCF yield of 3.90% , the current FCF yield is about 140.47% lower.
P/B
Median3y
1.06
Median5y
0.97
FCF Yield
Median3y
4.19
Median5y
3.90
Competitors Valuation Multiple
AI Analysis for SNY
The average P/S ratio for SNY competitors is 4.29, providing a benchmark for relative valuation. Sanofi SA Corp (SNY.O) exhibits a P/S ratio of 2.18, which is -49.21% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SNY
1Y
3Y
5Y
Market capitalization of SNY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SNY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SNY currently overvalued or undervalued?
Sanofi SA (SNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.18 is considered Undervalued compared with the five-year average of 10.14. The fair price of Sanofi SA (SNY) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 48.13 USD , Sanofi SA is Undervalued By Fair .
What is Sanofi SA (SNY) fair value?
SNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sanofi SA (SNY) is between +Inf to +Inf according to relative valuation methord.
How does SNY's valuation metrics compare to the industry average?
The average P/S ratio for SNY's competitors is 4.29, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.18, which is -49.21% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Sanofi SA (SNY) as of Jan 09 2026?
As of Jan 09 2026, Sanofi SA (SNY) has a P/B ratio of 1.39. This indicates that the market values SNY at 1.39 times its book value.
What is the current FCF Yield for Sanofi SA (SNY) as of Jan 09 2026?
As of Jan 09 2026, Sanofi SA (SNY) has a FCF Yield of 9.37%. This means that for every dollar of Sanofi SA’s market capitalization, the company generates 9.37 cents in free cash flow.
What is the current Forward P/E ratio for Sanofi SA (SNY) as of Jan 09 2026?
As of Jan 09 2026, Sanofi SA (SNY) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Sanofi SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sanofi SA (SNY) as of Jan 09 2026?
As of Jan 09 2026, Sanofi SA (SNY) has a Forward P/S ratio of 2.18. This means the market is valuing SNY at $2.18 for every dollar of expected revenue over the next 12 months.